WO2002022831A1 - Ribonuclease h thermotolerant - Google Patents
Ribonuclease h thermotolerant Download PDFInfo
- Publication number
- WO2002022831A1 WO2002022831A1 PCT/JP2001/007930 JP0107930W WO0222831A1 WO 2002022831 A1 WO2002022831 A1 WO 2002022831A1 JP 0107930 W JP0107930 W JP 0107930W WO 0222831 A1 WO0222831 A1 WO 0222831A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- polypeptide
- activity
- amino acid
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Definitions
- the present invention relates to polypeptides, and more particularly, to polypeptides having liponuclease H activity that are highly useful in genetic engineering.
- the present invention also relates to a gene useful for producing the polypeptide by genetic engineering. Further, the present invention relates to a method for producing the polypeptide by genetic engineering. Background art
- RNA degrading enzyme There are endo- and exo-types of ribonuclease (RNA degrading enzyme), with diverse substrate specificities and involved in complex biological activities. Enzymes that have a ribonuclease activity, lipoic nuclease I ⁇ , lipoic nuclease T 2, ribonuclease one Ze H, Riponukurea Ichize, ribonuclease I, ribonuclease II, ribonuclease III, lipoic nuclease IV, enzymes such as ribonuclease L is known Have been.
- Ribonuclease II (sometimes referred to herein as RNaseH) was first isolated from pup thymus by WH Stin and P. Hausen in 1969. At present, RNaseH is divided into cellular RNaseH, which is widely found in various animal cells, eukaryotes such as yeast, and prokaryotes such as Escherichia coli, and viral RNaseH, which is present in RNA tumor viruses. I have. Several types of RNaseH activities are present in one type of cell, and require a divalent metal ion such as Mg 2 + and Mn 2 + .
- E. coli-derived RNaseH is a hydrolase consisting of 155 amino acids and having a molecular weight of about 17 kDa, and has the substrate specificity of specifically cleaving only the RNA chain of the DNAZRNA hybrid in the end form.
- the resulting oligomer has a phosphate group at the 5 'end and a hydroxyl group at the 3' end.
- RNaseHI As a physiological function of RNaseHI, in replication of a ColEl plasmid, 1) degradation of RNA bound to a site other than the normal replication origin to ensure a normal replication origin, 2 ) It has been shown to synthesize RNA primers specific for the normal origin of replication. However, the function of RNaseHII is still unknown.
- RNaseH The importance of RNaseH is likely to increase with the development of genetic engineering.However, since the expression level of this enzyme in E. coli is extremely low, production of this enzyme by recombinant DNA technology is difficult. Attempts have already been made to supply RNaseH produced by recombinant DNA technology from BRL, Amersham Pharmacia Biotech, Takara Shuzo, and others.
- RNaseH Based on its substrate specificity, RNaseH has applications as exemplified below and is attracting attention as an extremely valuable enzyme.
- RNaseH which has heat resistance
- RNaseH derived from Escherichia coli has only lower productivity and enzyme activity than RNaseH derived from Escherichia coli, and its productivity is equal to or higher than that of Escherichia coli due to the expanded use of RNaseH.
- Development of RNaseH having heat resistance and enzymatic activity has been desired.
- An object of the present invention is to provide a polypeptide having RNaseH activity that is highly useful in genetic engineering, a gene encoding the polypeptide, and a method for producing the polypeptide by genetic engineering. . Summary of the Invention
- a first invention of the present invention relates to a thermostable liponuclease H polypeptide, which is selected from the following group, and which has a thermostable ribonuclease H activity: .
- the second invention of the present invention relates to a nucleic acid encoding a thermostable ribonuclease H, and relates to a nucleic acid selected from the following group and encoding a polypeptide having a thermostable ribonuclease H activity.
- nucleic acid comprising a base sequence having a deletion, addition, insertion or substitution
- nucleic acid (e) a nucleic acid according to any one of (a) to (d) or a nucleic acid capable of hybridizing with a phase capture chain thereof under stringent conditions;
- nucleic acid having a nucleotide sequence having at least 69% homology to the nucleotide sequence shown in any one of SEQ ID NOs: 8, 16, 22, 31, 36, 46, 56 or 58 in the sequence listing.
- a third invention of the present invention relates to a recombinant DNA, which is characterized in that it comprises the nucleic acid of the second invention.
- a fourth invention of the present invention relates to a transformant, which is characterized by being transformed by the recombinant DNA of the third invention.
- a fifth invention of the present invention relates to a method for producing a polypeptide having a thermostable liponuclease activity, comprising culturing the transformant of the fourth invention, and producing a polypeptide having a thermostable liponuclease activity from the culture. It is characterized by collecting peptides.
- a transformant into which any one of the plasmids pRHB11, pBCA3Nd2, pPFU220, pTM-RNH, pPH0238, pAFU204, pTLI204 or pTCE207 has been introduced is cultured.
- the present invention relates to the resulting polypeptide having thermostable liponuclease H activity.
- RNase H is a hydrolase having a substrate specificity of specifically cleaving only the RNA strand of a DNA / RNA hybrid in an end form, and the generated oligomer has a 5′-terminal. And those with a hydroxyl group at the end.
- the polypeptide has heat-resistant RNase H activity, but the polypeptide has RNase H activity even after being kept at a temperature of 60 ° C or more for 15 minutes.
- the heat resistance RNase H3 ⁇ 4 ⁇ production can be measured, for example, as follows. Poly (rA) and poly (dT) (both from Amersham Phanoremasia Biotech) lmg each containing 4 mM Tris-HC1 (H
- reaction solution [2 OmM potassium potassium hydroxide (pH 8.5), 0.01% bovine serum albumin (Takara Shuzo) was pre-incubated with 1 ⁇ l of the enzyme solution whose activity was to be measured at 40 ° C. 1% dimethyl sulfoxide, 4 mM magnesium acetate, 20 ⁇ g / 1 poly (dT) (Amersham Pharmacia by Saisai-Tech), 30 ⁇ g / 1 poly (rA) (Amersham Pharmacia) Add 100 ⁇ l, incubate at 40 ° C for 10 minutes, stop the reaction with 0.5 ⁇ M EDTA (pH 8.0), 10 ⁇ l, and measure the absorbance at 260 nm. Thereby, the thermostable RNaseH activity of the present invention can also be measured.
- RNase H One unit (RN) of RNase H is equivalent to the release of 1 nmol of liponucleotide A 26 .
- Unit (unit) [absorbance difference X reaction volume (ml)] / 0.012
- polypeptide of the present invention is represented by any one of SEQ ID NOs: 9, 17, 23, 32, 37, 47, 57 or 59 in the sequence listing as long as the polypeptide exhibits heat-resistant RNaseH activity. And at least one amino acid residue is deleted, added, inserted, or substituted in the amino acid sequence.
- polypeptides lack polyamino acids in their amino acid sequences due to polymorphisms and mutations in the DNA encoding them, as well as modification reactions in vivo and during purification of the produced polypeptides. Mutations such as loss, insertion, addition, and substitution can occur. However, when such a mutation is present in a portion that is not important for the activity or retention of the structure of the polypeptide, the physiological and biological properties are substantially equivalent to those of the polypeptide having no mutation. It is known that there are indications of activity 14.
- polypeptides are known to have peptide regions that are not essential for activity. For example, signal sequences present in polypeptides secreted extracellularly, prosequences or presequence sequences found in protease precursors, etc. It is removed upon conversion to the polypeptide. Such a polypeptide is a 7 fire structure These are polypeptides that exist in different forms, but ultimately perform the same function.
- genes having the nucleotide sequences shown in SEQ ID NOs: 8, 16, 22, 31, 36, 46, 56 or 58 in the Sequence Listing isolated by the present invention include SEQ ID NOs: 9, 17, and 23 in the Sequence Listing, respectively.
- 32, 37, 47, 57 or 59 are encoded, and the polypeptide has heat-resistant RNase H activity. Accordingly, polypeptides from which peptide regions that are not essential for activity have been deleted are also included in the polypeptides of the present invention.
- a peptide chain irrelevant to the activity of the polypeptide may be added to the amino terminal or carboxyl terminal of the target polypeptide.
- a fusion polypeptide in which a part of the amino terminal region of the polypeptide highly expressed in the host used is added to the amino terminal of the target polypeptide.
- Peptides may be produced.
- a peptide having an affinity for a specific substance has been added to the amino or carboxyl terminus of the target polypeptide.
- polypeptide having the amino acid sequence is within the scope of the present invention as long as it has heat-resistant RNaseH activity.
- the above homology can be determined, for example, by using the computer program DNAS I S-Mac (manufactured by Takara Shuzo) and the computer algorithm FAS TA (version 3.0; (Pearson, WR) et al., Pro. Natl. Acad. Sci., 85: 2444-2448, 1988), Combinatoriale Bollastism B LAST (version 2.0; Altschul et al., Nucleic Acids Res. 25: 3389-3402). , 1997).
- the polypeptide of the present invention includes, for example, (1) purification from a culture of a microorganism producing the polypeptide of the present invention, and (2) culture of a transformant containing a nucleic acid encoding the polypeptide of the present invention. Can be produced by a method such as purification from
- DSM406 Cardotenax
- DSM36 38 Pyrococcus furiosus
- DSM3 109 Thermotoga Maritima
- Anoreca Globus Frugidas DSM4 139
- Thermococcus litoraris D
- the culture of the microorganism may be performed under conditions suitable for the growth of the microorganism, and preferably, culture conditions that increase the expression level of the target polypeptide are used.
- the target polypeptide thus produced in the cells, or in the culture solution, can be purified by a method generally used for protein purification.
- a method usually used for culturing a heat-resistant bacterium can be used, and the nutrient added to the medium may be any one that can be used by the strain.
- the carbon source for example, starch and the like can be used, and as the nitrogen source, for example, tryptone, peptone, yeast extract, and the like can be used.
- Metal salts such as magnesium salts, sodium salts, and iron salts may be added to the medium as trace elements.
- Cultivation can be performed by static culture or stirred culture.
- static culture or stirred culture.
- stirred culture for example, Applied and Applied and Micronology
- a dialysis culture method may be used as described in Environmental Microbiology, Vol. 55, pp. 208-6-2088 (1992).
- the culturing conditions and culturing time are preferably set so as to maximize the polypeptide production according to the strain used and the medium composition.
- a cell-free extract is prepared.
- the cell-free extract can be prepared, for example, by collecting cells from the culture by centrifugation, filtration, and the like, and then disrupting the cells.
- a method of crushing the cells a method having a high effect of extracting the target enzyme may be selected from ultrasonic crushing, bead crushing, lysing enzyme treatment and the like.
- the polypeptide in the culture supernatant is concentrated by ammonium sulfate precipitation, ultrafiltration, etc., and extracted without cells. Liquid.
- a method generally used for protein purification can be used. For example, a combination of ammonium sulfate salting-out treatment, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography and the like can be used in combination.
- polypeptide having the amino acid sequence represented by SEQ ID NO: 9 is derived from the nucleotide sequence represented by SEQ ID NO: 8, and the polypeptide having the amino acid sequence represented by SEQ ID NO: 17 is represented by the nucleotide sequence represented by SEQ ID NO: 16.
- polypeptide of the amino acid sequence represented by SEQ ID NO: 23 was obtained, and from the nucleotide sequence represented by SEQ ID NO: 31, the polypeptide of the amino acid sequence represented by SEQ ID NO: 32 was represented by:
- the polypeptide of the amino acid sequence of SEQ ID NO: 37 is derived from the nucleotide sequence of SEQ ID NO: 36, and the polypeptide of the amino acid sequence of SEQ ID NO: 47 is derived from the nucleotide sequence of SEQ ID NO: 46.
- polypeptide of the amino acid sequence of SEQ ID NO: 57 is derived from the nucleotide sequence of SEQ ID NO: 56
- polypeptide of the amino acid sequence of SEQ ID NO: 59 is derived from the nucleotide sequence of SEQ ID NO: 58. Lipeptides are produced respectively.
- pTM- RNH be purified p PHO 238 N pAFU204, pTL I 204 or polypeptide of any one the introduced culture obtained by culturing the transformant or et present invention p TCE 207 Good.
- the host to be transformed is not particularly limited, and is usually used in the field of recombinant DNA, such as Escherichia coli, Bacillus subtilis, yeast, filamentous fungi, plants, animals, plant cultured cells, animal cultured cells, etc. Host.
- the polypeptide of the present invention can be prepared by subjecting Escherichia coli having a plasmid in which the nucleic acid of the present invention is ligated downstream of the 1 ac promoter or T7 phage promoter to normal culture conditions, for example, 100 ⁇ g / ml After culturing at 37 ° C in LB medium containing ampicillin (10 gZ liter of tryptone, 5 gZ liter of yeast extract, 5 g / liter of NaC, pH 7.2) at 37 ° C until the logarithmic growth phase, the concentration becomes 1 mM. By adding isopropyl- ⁇ -D-thiogalatatoviranoside and further culturing at 37 ° C, the polypeptide can be expressed in the cultured cells.
- the cells collected by centrifugation are disrupted by ultrasonic waves, and then centrifuged. And collect the supernatant to obtain a cell-free extract.
- the cell-free extract shows thermostable RNaseH activity.
- the polypeptide of the present invention can be purified from the cell-free extract by using known methods such as ion exchange chromatography, gel filtration, hydrophobic chromatography, and ammonium sulfate precipitation.
- the partially purified product obtained in the above-mentioned purification process also naturally exhibits RNaseH activity.
- the polypeptide of the present invention expressed in Escherichia coli carrying the plasmid linked with the nucleic acid of the present invention has heat resistance, it can be used as a purification means for cultured cells and / or cell-free extracts.
- a heat treatment at a temperature of 40 ° C. or higher for about 10 minutes may be performed to remove the host-derived protein which has been denatured and insolubilized by heat. Further, the temperature and time of this heat treatment may be appropriately selected as appropriate.
- the polypeptide of the present invention is expressed at room temperature, for example, at 37 ° C. using a transformant holding a nucleic acid encoding the polypeptide, the obtained expression is obtained.
- the product retains its activity, heat resistance, etc. That is, the polypeptide of the present invention can form its own higher-order structure even when expressed at a temperature different from the temperature at which the original producing bacteria grow.
- the nucleic acid of the present invention is a nucleic acid encoding the polypeptide of the present invention, and specifically, any one of SEQ ID NOs: 9, 17, 23, 32, 37, 47, 57 and 59 in the sequence listing. Or an amino acid sequence in which at least one of one or more amino acid residues has been deleted, added, inserted or substituted in said sequence, and said heat-resistant RNase H
- a nucleic acid encoding a polypeptide showing activity (1) a nucleic acid represented by the base sequence of any one of SEQ ID NOs: 8, 16, 22, 31, 36, 46, 56 or 58 in the sequence listing Is capable of hybridizing under stringent conditions to (2) and the above nucleic acid (1) or (2), or is at least 69%, preferably 80%, and more preferably the nucleotide sequence of (1) or (2). Is a nucleotide sequence with 90% homology and exhibits heat-resistant RNase H activity It is a nucleic acid (3) or the like which encode polypeptide.
- nucleic acid means single-stranded or double-stranded DNA or RNA.
- nucleic acid (2) is RNA, it is represented by, for example, a nucleotide sequence in which T is replaced by U in the nucleotide sequence described in SEQ ID NO: 8 in the sequence listing.
- the nucleic acid of the present invention can be obtained, for example, as follows.
- nucleic acid (2) represented by the nucleotide sequence described in any one of SEQ ID NOs: 8, 16, 22, 31, 36, 46, 56, or 58 in the sequence listing is included in the description of the polypeptide of the present invention.
- Bacillus caldotenatas (DSM4066), Pyrococcus furiosas (DSM3638), Thermotoga maritima (DSM3109), Arcaeoglobus fulgidas (DSM4139), Saimococcus li tralis (DSM5473), Thermococca (DSM5473) cultured by the described method DS
- genomic DNA can be prepared according to a standard method, and isolated from a DNA library prepared using the same.
- genomic DNA was represented by the nucleotide sequence of any one of SEQ ID NOs: 8, 16, 22, 31, 36, 46, 56 or 58 in the polymerase chain reaction (PCR) using the DNA as type II. It can also be obtained by amplifying the nucleic acid obtained.
- nucleotide sequence of the nucleic acid encoding the polypeptide of the present invention provided by the present invention, for example, any one of SEQ ID NOs: 8, 16, 22, 31, 36, 46, 56 or 58 in the sequence listing. Based on the described nucleotide sequence, it is also possible to obtain a nucleic acid encoding a polypeptide having the same heat-resistant RNase H activity as the polypeptide of the present invention. That is, by using a nucleic acid encoding the polypeptide of the present invention or a part of the base S1 thereof as a hybridization probe, a DNA encoding a polypeptide having a heat-resistant native RNaseH activity can be obtained from cells.
- the extracted DNA, and the DNA was obtained as type III; screening can be performed from PCR products and the like.
- a DNA encoding a polypeptide having a thermostable RNaseH activity can be amplified by using a gene amplification method such as PCR using a primer designed from the above nucleotide sequence. It is also possible to chemically synthesize a DNA encoding a polypeptide having heat-resistant RNase H activity.
- the nucleic acid (1) or (3) can be obtained.
- a nucleic acid fragment containing only a part of the target nucleic acid may be obtained.
- PCR is performed using a primer synthesized using the force of hybridization or a primer synthesized based on the nucleotide sequence of the nucleic acid fragment. Obtaining the entire nucleic acid is easier.
- hybridize under stringent conditions refers to 1989, published by Cold Spring Harbor Laboratory, edited by T. Maniatis, et al., Molecular cloning: Molecular Laboratory, 2nd Edition (Molecular) Cloning: means that hybridization is possible under the conditions described in A Laboratory Manual 2nd ed.), Etc. For example, means that hybridization is possible under the following conditions.
- the "stringent conditions” are not particularly limited, and include, for example, 6XSSC, 0.5% SDS, 5X Denhardt, 0.01% denatured salmon sperm nucleic acid In the solution, it means the condition to keep the temperature of 1B at [Tm-25 ° C].
- Tm 81.5-16.6 (log 10 [Na + ]) +0.41 (° / oG + C) -one (600 / N) (where N is the oligonucleotide probe or primer % G + C is the content of guanine and cytosine residues in the oligonucleotide probe or primer.)
- T m is, for example, the product of the content of A + T (adenine + thymine) residue and 2 ° C. and the G + C residue. It can be estimated from the sum of the product of the group content and the product of 4 ° C, C (A + T) X2 + (G + C) X4].
- a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid encoding the polypeptide of the present invention does not have to have the same nucleotide sequence as the nucleotide sequence disclosed herein. However, as described above, it is included in the scope of the present invention as long as it encodes a polypeptide showing heat-resistant RNase H activity.
- nucleic acids are never stable in nature, and mutations in their nucleotide sequences are not uncommon. In some cases, a mutation occurring on a nucleic acid does not change the amino acid sequence encoded therein (called a silent mutation). In this case, it can be said that different nucleic acids encoding the same amino acid sequence have been generated.
- nucleic acid encoding a specific amino acid sequence is isolated, it is undeniable that many types of nucleic acids encoding the same amino acid sequence will be produced as the organism containing the nucleic acid is passaged. . Furthermore, it is not difficult to artificially produce various types of nucleic acids encoding the same amino acid sequence by using various genetic engineering techniques.
- Recombinant DNA can be prepared by ligating a nucleic acid encoding the polypeptide of the present invention, for example, a nucleic acid having the nucleotide sequence of SEQ ID NO: 7 in the sequence listing, to an appropriate vector.
- a vector used for producing the recombinant DNA there is no particular limitation on the vector used for producing the recombinant DNA, and for example, a plasmid vector, a phage vector, a virus vector and the like can be used.
- An appropriate vector is used according to the purpose of use of the recombinant DNA. Just choose.
- a transformant can be prepared by introducing the recombinant DNA into an appropriate host.
- the host used for preparing the transformant is not particularly limited, and microorganisms such as bacteria, yeast, and filamentous fungi, as well as cultured cells of animals, plants, insects, and the like can be used. By culturing the transformant to produce the polypeptide of the present invention in a culture, the polypeptide of the present invention can be produced in a large amount.
- the culture was centrifuged (5000 X g, 15 minutes) and collected. Wet cell weight of 402 g was added to 1 OmM mercaptoethanol, 0.5 M NaCl, and 1 mM ED. TA, 20 // 5 OmM Tris-HC1 buffer (pH 7.5) containing M PAPMSF suspended in 100 Om1 and disrupted with MINI-Lab (APV GAUL IN / RAN NIE) Thereafter, cell debris was removed by centrifugation, and the supernatant was recovered. A polyethyleneimine solution was added to the obtained supernatant to a final concentration of 0.1%. After stirring, the mixture was allowed to stand for 1 hour, and the supernatant was collected by centrifugation.
- the buffer was further washed with 42 Om1 of the buffer used for equilibration, and the washed fraction was collected.
- the non-adsorbed fraction and the washed fraction from the DE52 column chromatography were mixed, and 1 OmM Menole Captoethanol, 0.1 mM EDTA, 5 OmM NaCl, and 2 OmM Tris-HC containing 10% glycerol were added.
- the obtained active fraction was placed in a dialysis tube, placed on a solid polyethylene dariconore 20 000, and dehydrated and concentrated at 4 ° C. Next, 30 Om 1 of SuperEdex was equilibrated with 25 mM Tris-HC1 buffer (pH 7.5) containing 5 mM mercaptoethanol, 0.5 mM EDTA, 3 OmM NaCl, and 10% glycerol.
- the G_200 column (Amersham Pharmacia Biotech) was loaded with this enzyme concentrate. Elution was performed with the buffer used for equilibration, and an active fraction was obtained.
- a 15 ml Heparin-Sepharose column (Amersham Fanolema) equilibrated with 2 OmM Tris-HC1 buffer (pH 7.5) containing 10 mM mercaptoethanol, 0.1 ImM EDTA, 5 OmM NaCl, and 10% glycerol
- the active fractions were loaded on a BioBiotech) and eluted with an equilibration buffer containing 0 to 0.5 M NaCl.
- the obtained active fraction was diluted with 2 OmM Tris-HC 1 buffer containing 1 OmM mercaptoethanol, 0. ImM EDTA, 5 OmM NaCl, and 10% glycerol.
- the solution was loaded on a 5 ml Hitrap-SP column (manufactured by Amersham Pharmacia Biotech) equilibrated with (pH 7.5) and eluted with an equilibration buffer containing 0 to 0.5 M NaCl.
- the obtained active fraction was again equilibrated with 25 mM Tris-HC1 buffer (pH 7.5) containing 5 mM mercaptoethanol, 0.5 mM EDTA, 3 OmM NaCl, and 10% glycerolone (300 ml).
- Thermostability RNaseH activity was measured by the following method.
- Poly (rA) —1 ⁇ l of enzyme solution was added to 100 / i1 of poly (dT) solution, reacted at 40 ° C. for 10 minutes, and stopped by adding 0.5M EDTA 101. Thereafter, the absorbance at 260 nm was measured.
- 10 ⁇ l of 0.5 M EDTA was added to the above reaction solution, and the mixture was reacted at 40 ° C. for 10 minutes, and the absorbance was measured. Thereafter, a value (absorbance difference) was obtained by subtracting the absorbance of the control from the absorbance determined by reacting in the absence of EDTA.
- the concentration of nucleotides released from the poly (rA) -poly (dT) hybrid by the enzymatic reaction was determined from the difference in absorbance.
- One unit of RNaseH is equivalent to 1 nmo1 of ribonucleotide released A 26 .
- the value of the following equation was corrected by the dilution ratio.
- Unit (unit) [absorbance difference X reaction volume (m 1)] ⁇ . 0 1 52
- Bacillus cardotenax YT-G strain (DSM406) was inoculated into 60 ml of LB medium (1% tryptone, 0.5% yeast extract, 0.5% NaCl, H7.2), and 65 ° C, Incubated for 20 hours. After completion of the culture, the culture was centrifuged to collect the bacteria. The obtained cells were cultured in 2 ml of 25% sucrose, 50 mM Tris-HC1 (pH 8.
- oligonucleotide BsuI1-3 SEQ ID NO: 1
- oligonucleotide BsuII-6 SEQ ID NO: 2
- Bacillus cardotenax genomic DNA prepared in Example 2 (1) above The solution (1 ⁇ l) was made into type III, and PCR was performed in a volume of 100 ⁇ l using B sul I-3 of lO Opmo 1 and Bsu II-6 of 100 pmo 1 as primers.
- DNA For DNA polymerase in CR use Takara Tack (Takara Shuzo Co., Ltd.) according to the attached protocol.PCR is performed at 94 ° C for 30 seconds, 45 ° C for 30 seconds, and 72 ° C for 1 minute as one cycle. 50 cycles were performed. After completion of the reaction, the reaction solution was subjected to phenol treatment and ethanol precipitation to purify DNA.
- the obtained DNA was blunt-ended using T4 DNA polymerase (manufactured by Takara Shuzo), followed by agarose gel electrophoresis, and the amplified DNA fragment of about 0.4 kb was recovered from the gel.
- the obtained DNA fragment of about 0.4 kb was ligated to pUC119 (Takara Shuzo) digested with SmaI (Takara Shuzo) using T4 DNA ligase (Takara Shuzo), and E. coli JM 109 were transformed.
- This transformant was cultured to obtain plasmid 21-12 into which a DNA fragment of about 0.4 kb was inserted.
- oligonucleotide nucleotide RNII-S1 SEQ ID NO: 3
- oligonucleotide RNII-S2 SEQ ID NO: 4
- Example 2 Bacillus canoledotenax genomic DNA prepared in (1) was digested with BamHI (Takara Shuzo), and the resulting BamHI digest and S au3 AI force set (Takara Shuzo) were obtained. Is ligated with T4 DNA ligase, and this is used as type II, and RNII-S2 is used as a primary PCR primer and RNI I_S1 is used as a secondary PCR primer. Takara LA PCR In vitro Cloning Kit (Takara Shuzo Co., Ltd.) The operation was performed according to the protocol attached to ().
- the DNA was purified from the secondary PCR solution by phenol treatment and ethanol precipitation, the ends of the DNA were blunted using T4 DNA polymerase, and then agarose gel electrophoresis was performed. Was recovered from the gel. The resulting 1.5 kb DNA fragment was digested with SmaI; ligated to pUC119 using T4 DNA ligase to transform E. coli JM109.
- This transformant is cultured, and a plasmid into which a DNA fragment of about 1.5 kb has been inserted. B 25N 16 was obtained.
- the oligonucleotides RNII-S5 (SEQ ID NO: 5) and the oligonucleotides RNII-S6 (SEQ SEQ ID NO: 6) was synthesized.
- PCR was performed using plasmid 21-12 prepared in Example 2- (2) as type III and RNI I-S5 and RNII-S6 as primers.
- the DNA polymerase used in PCR was Takara Ex tack (Takara Shuzo Co., Ltd.) according to the attached protocol.
- the PCR was performed at 94 ° C for 30 seconds, 55 ° C for 30 seconds, and 72 ° C for 30 seconds as one cycle. 25 cycling went. After the reaction was completed, agarose gel electrophoresis was performed.
- a 0.3 kb DNA fragment was recovered from Genore.
- the obtained DNA fragment of about 0.3 kb was labeled with digoxigenin using dig high prime (manufactured by Roche Diagnostics).
- the Bacillus canoledotenax genomic DNA prepared in Example 2_ (1) was digested with Hind III (Takara Shuzo), Sac I (Takara Shuzo), and Hindlll and S acl was double digested, and the resulting digest was subjected to Southern hybridization.
- Hybridization and detection were performed using a DIG luminescent detection kit (manufactured by Roche Diagnostics) according to the attached protocol. As a result, a DNA fragment of about 4.5 kb was obtained for Hind III digestion, a DNA fragment of about 5.8 kb was obtained for Sacl digestion, and a DNA fragment of about 1.3 kb was obtained for double digestion of Hindlll and Sacl. Hybridized with probe.
- Bacillus caldotenax genomic DNA was digested with Hindi II and subjected to agarose gel electrophoresis, and a DNA fragment of about 4.5 kb was recovered from the gel.
- the obtained DNA fragment was digested with SacI and subjected to agarose gel electrophoresis, and a DNA fragment of around 1.3 kb was recovered from the gel.
- This DNA fragment was ligated to pUC19 (manufactured by Takara Shuzo) digested with Hindlll and Sacl using T4 DNA ligase to transform Escherichia coli HB101.
- B25N16 prepared in Example 2-(3) was digested with HindiII and subjected to agarose gel electrophoresis, and then a DNA fragment of about 160 bp was recovered from the gel.
- the obtained DNA fragment of about 160 bp was ligated to the above-prepared HindIII digest of pRHB1 using T4 DNA ligase to transform Escherichia coli HB101.
- a plasmid was prepared from the obtained transformant.
- oligonucleotide RNII-Nde (SEQ ID NO: 7) was synthesized based on the expected nucleotide sequence around the initiation codon, and the plasmid prepared from the transformant obtained above was designated as type III. PCR was performed using RN II—Nde and RN II—S6 as primers. At this time, a plasmid having a DNA fragment of about 0.7 kb was selected, and this plasmid was designated as pRHB11.
- the nucleotide sequence of the DNAHf fragment inserted into the thus obtained plasmid pRHB11 was determined. Analysis of the results revealed an open reading frame (0RF) that was thought to encode RNaseHII.
- the nucleotide sequence of this open reading frame is shown as SEQ ID NO: 8 in the sequence listing.
- the amino acid sequence of RNaseHII deduced from the nucleotide sequence is shown in SEQ ID NO: 9 in the sequence listing.
- Escherichia coli HB101 transformed with pRHB11 or pRHB1 was inoculated into 5 ml LB medium containing 100 / ig / ml ampicillin, and cultured at 37 ° C with shaking for 1 °. After completion of the culture, the cells collected by centrifugation were suspended in 0.5 ml of TE buffer and sonicated, and a supernatant was obtained by centrifugation to obtain a crude cell extract.
- Example 2 E. Coli HB101 transformed with pRHB11 obtained in (4) was inoculated into 11 LB medium containing 100 // g / m1 ampicillin, and then inoculated at 37 ° C. For 16 hours. After completion of the culture, the cells collected by centrifugation were collected in a 52.3 ml sonication buffer (50 mM Tris_HC1 (pH 8.0), 2 mM 2-menolecaptoethanol, 10% glycerol, 2 mM Phenylene methanesulfonyl fluoride] and sonicated. This crushed liquid is centrifuged at 1200 rpm for 10 minutes, and the obtained supernatant is heated at 60 ° C for 15 minutes. Made sense. Thereafter, the mixture was centrifuged again at 12000 rpm for 10 minutes, and the supernatant was collected to obtain a heat-treated supernatant of 50.Om1.
- 52.3 ml sonication buffer 50 mM Tris
- the eluate was eluted with a linear gradient of 0 to 50 OmM NaCl using an FPLC system to obtain an RNaseHII fraction eluted at about 24 OmM NaCl.
- the RNaseHII fraction (3.0 ml) was divided into two portions, and applied to a PD-10 column (Amersham Pharmacia Biotech) equilibrated with buffer C containing 50 mM NaC1.
- Eluate 7.Om 1 was applied to a HiTra ph eparin column (manufactured by Amersham Pharmacia Biotech) equilibrated with Buffer O containing 5 OmM NaC1, and 50-55 OmM using FP LC system.
- An RNaseHII fraction eluted at approximately 31 OmM NaCl was eluted with a linear gradient of NaCl.
- the RNaseHII fraction 4.4 ml was concentrated by ultrafiltration using Centricon-1 10 (manufactured by Amicon), and 280 ⁇ l of the concentrated solution was subjected to 10 OmM NaC1, 0. ImM EDTA.
- the solution was applied to a Superdex 200 gel filtration column (manufactured by Amersham Pharmacia Biotech) equilibrated with 5 OmM Tris-HC1 (pH 8.0) and eluted with the same buffer.
- RNaseHII was 35 kilodaltons.
- the RNaseHII eluted in this manner was used as a BcaRNaseSeHII standard.
- enzyme activity was measured by the following method.
- B ca RNase HII sample Reaction solution pre-incubated in 1 ⁇ l at 40 ° C [20 ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ pH (pH 7.8), 0.01% bovine serum albumin ( Takara Shuzo), 1% dimethyl sulfoxide, 10 mM manganese chloride, 20 gZml poly (dT) (Amersham Pharmacia Biotech), 30 ig / ml poly (rA) (Amersham Pharmacia Biotech)) ⁇ ⁇ ⁇ After adding ⁇ and reacting at 40 ° C for 10 minutes, 0.5M EDTA
- Example 2 200 ng of Bacillus cardotenax genomic DNA prepared in (1) was converted into type II, and lO O pmol BsuIII-1 and 100pmo1
- the first PCR was performed at a volume of 50 / i1 using BsuIII-18 as a primer. Further, using the reaction solution 1 i 1 as a ⁇ type, a second PCR was carried out at a volume of 1001 using l OO pmol Bsu III-3 and l OO pmol B su III _6 as primers. . Takara Tack (Takara Shuzo) was used as the DNA polymerase in these two PCRs according to the attached protocol. The first PCR was performed at 94 ° C for 30 seconds, at 45 ° C for 30 seconds, and at 72 at 72 ° C. Each cycle was a cycle of 25 cycles, and the second cycle was a cycle of 30 cycles.
- the DNA fragment of about 450 bp obtained by amplification was blunt-ended using T4 DNA polymerase (Takara Shuzo), followed by agarose gel electrophoresis. A 50 bp DNA fragment was recovered.
- the obtained DNA fragment of about 450 bp was ligated to pUC119 (Takara Shuzo) digested with SmaI (Takara Shuzo) using T4 DNA ligase (Takara Shuzo), E. coli J Ml09 was transformed.
- the transformant was cultured to obtain a plasmid pBCA3204 into which a DNA fragment of about 450 bp was inserted.
- Example 3 The nucleotide sequence of the DNA fragment inserted into pBCA3204 obtained in (1) was determined, and primer RNIII—S3 (SEQ ID NO: 14) was determined based on the obtained sequence. And B ca RNIII-3 (SEQ ID NO: 15) were synthesized. This primer RN I
- BCA3204 was made into a ⁇ type, and PCR was performed with a volume of 100 ⁇ l.
- the DNA polymerase used in the PCR was Takara Petac (Takara Shuzo Co., Ltd.) according to the attached protocol. PCR was performed at 98 ° C for 0 second, at 55 ° C for 0 second, and at 72 ° C for 20 seconds. The thirty-three cycle went. After completion of the reaction, phenol was extracted with a form of chloroform, followed by ethanol precipitation. Then, agarose gel electrophoresis was performed, and a DNA fragment of about 0.4 kb was recovered from the gel. The obtained DNA fragment of about 0.4 kb was labeled with a DIG DNA labeling kit (manufactured by Behringer Mannheim) to prepare a probe.
- a DIG DNA labeling kit manufactured by Behringer Mannheim
- the membrane is then washed twice with 5 Om 1 in 0.1% SDS in 2 XSSC (17.5 g / l NaC1, 7.7 g / sodium citrate) at room temperature, 50 ml of 0 After washing twice at 45 ° C in 0.5 XSSC (4.4 g Z1 sodium salt, 1.9 g / l sodium citrate) containing 1% SDS, DIG nucleic acid detection kit (Boehringer Mannheim) , An approximately 8 kb EcoRI fragment, an approximately 4.5 kb PstI fragment, and an approximately 1 kb HindIII fragment having a rooster sequence complementary to the probe were detected.
- PCR was performed in a volume of 501, and colonies considered to have the RNaseHIII gene were selected.
- PCR was performed using Takara Z Tack (Takara Shuzo Co., Ltd.) according to the attached protocol. went. As a result, it was found that the target gene was contained in the colonies No. 88 and 88.
- a plasmid was prepared from the No. 88 coloie, and this was transformed into a type I primer, RV-N (Takara Shuzo) and Bca RNI I 1-3 or primer M4 (Takara Shuzo) and RN III — PCR was performed using S3 to check whether the entire length of the RNAseHI II gene was included. As a result, it was predicted that the entire length of RNaseHIII was included from the chain length of the amplification product.
- This plasmid was designated as PBCA3 P88.
- the nucleotide sequence of the inserted DNA fragment of the plasmid pBCA3P88 obtained in Example 3 (2) was determined by the dideoxy method.
- Plasmid pBCA3 P88 described in Example 3 _ (2) was transformed into a ⁇ type, and B ca RNIII Nde (sequence was set with reference to the rooster sequence around the RNaseHIII open reading frame obtained above).
- PCR was carried out using No. 18) and M13 primer M4 (Takara Shuzo) in a volume of 100 ⁇ l.
- M13 primer M4 Takara Shuzo
- DNA polymerase in PCR use Pi-Vest DNA polymerase (Takara Shuzo) according to the attached protocol, PCR for 30 seconds at 94 ° C, 30 seconds at 55 ° C, and
- PCR was carried out in a volume of 501 to select colonies that are thought to have the RNaseHIII gene.
- DNA polymerase in PCR use Takara Z-Tac (Takara Shuzo) according to the attached protocol. PCR was performed at 30 cycles of 98 seconds at 0 seconds, 55 ° C for 0 seconds, and 72 ° C for 20 seconds. I went cycling.
- the Colloe No. 2 had a plasmid in which the RNaseHIII gene in the NdeI fragment was connected downstream of the 1 ac promoter of the pTV119Nd vector, and this plasmid was designated as pBCA3Nd2 It was decided.
- nucleotide sequence of the inserted DNA fragment in the plasmid was confirmed by the dideoxy method. However, it was confirmed that there was no mutation caused by PCR except that the start codon was changed from GTG to ATG.
- Escherichia coli JM109 transformed with plasmid pBCA3Nd2 was named and displayed as Escherichia coli J1109 / pBCA3Nd2, and from September 5, 2000 (Hara Deposit Date), Tsukuba, Tokyo, 305-8566, Ibaraki, Japan 1-chome No. 1 1 Chuo No. 6, deposited at the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary under the accession number FE RM BP-7653.
- Example 3- obtained in (4): E. coli JM109 transformed with BCA3Nd2 was inoculated into 21 LB medium containing 10 g / m1 ampicillin, and
- the cells were cultured with shaking for 16 hours. After completion of the culture, the cells collected by centrifugation were transferred to 39.6 ml of a sonication buffer [5 OmM Tris-HC1 ( ⁇ H8.0), 1 mM EDTA, 2 mM phenylmethanesulfur fluoride. And sonicated. This crushed liquid was centrifuged at 12000 rpm for 10 minutes, and the obtained supernatant was subjected to a heat treatment at 60 ° C for 15 minutes. Thereafter, centrifugation was again performed at 1200 rpm for 10 minutes, and the supernatant was collected to obtain 39.8 ml of the heat-treated supernatant.
- a sonication buffer [5 OmM Tris-HC1 ( ⁇ H8.0), 1 mM EDTA, 2 mM phenylmethanesulfur fluoride. And sonicated. This crushed liquid was centrifuged at 12000 rpm for 10 minutes, and the obtained super
- 7.5 ml of the passed RNase HIII fraction was concentrated by ultrafiltration using Centricon 10 (manufactured by Millipore), and 190 ⁇ l of the concentrated solution was concentrated to 100 mM NaCl, 0.1 mM.
- the solution was applied to a Superdex 200 gel filtration column (manufactured by Amersham Pharmacia Biotech) equilibrated with 50 mM Tris-HC1 (pH 7.0) containing EDTA, and eluted with the same buffer.
- the RNase HIIII thus eluted was used as a Bca RNase HHIII standard.
- the enzymatic activity was measured by the following method using the BcaRNase HIIII standard obtained above.
- the obtained cells were suspended in 4 ml of 25% sucrose, 50 mM Tris-HC1 (H 8.0), and 0.4 ml of an aqueous solution of 1 OmgZm1 salted phyllolysozyme (manufactured by Nacalai Tesque) was added. In addition, the reaction was carried out at 20 ° C for 1 hour. After the reaction is complete, add 24 ml of 150 mM NaCl, 1 mM EDTA, 20 mM Tris-HC
- primers 1650 Nde SEQ ID NO: 20
- 165 OB am SEQ ID NO: 21
- Example 4 200 ng of Pyrococcus furiosus DNA obtained in (1) was transformed into a type II, and PCR was carried out in a volume of 1001 using 20 praol of 1650 Nde and 20 pmol of 1650 Bam as a primer.
- Takara Ex tack (Takara Shuzo Co., Ltd.) was used according to the attached protocol, and PCR was performed at 94 ° C for 30 seconds, 55 ° C for 30 seconds, and 72 ° C for 1 minute as one cycle. For 30 cycles.
- the amplified DNA fragment of about 0.7 kb was digested with NdeI and BamHI.
- Example 4 The nucleotide sequence of the DNA fragment of pPFU220 obtained in step (2) was determined by the didoxy method.
- Example 4 E. coli HMS174 (DE3) (manufactured by Novagen) was transformed with pPFU220 obtained in (2), and 100 ⁇ g of E. coli HMS174 (DE3) containing pPFU220 was obtained. / m 1 of ampicillin in 21 LB medium The cells were cultured and shake-cultured at 37 ° C for 16 hours. After completion of the culture, the cells collected by centrifugation were placed in a 66.Om1 sonication buffer (5 OmM Tris-HC1 (H8.0), ImM EDTA, 2 mM phenylmethanesulfonyl phenolic). Suspended and sonicated.
- a 66.Om1 sonication buffer 5 OmM Tris-HC1 (H8.0), ImM EDTA, 2 mM phenylmethanesulfonyl phenolic.
- This crushed liquid was centrifuged at 12000 rpm for 10 minutes, and the obtained supernatant was subjected to a heat treatment at 80 ° C for 15 minutes. Thereafter, the mixture was centrifuged again at 12000 rpm for 10 minutes, and the supernatant was collected to obtain 61.5 ml of a heat-treated supernatant.
- the heat-treated supernatant was applied to a RES OU RSEQ column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer A [5 OmM Tris_HC1 (pH 8.0), ImM EDTA], and the F PLC system (Amersham Pharmacia Biotech) was used. (Manufactured by KK). As a result, the RNAse HII passed through the RE SOUR SEQU column.
- the passed RNase HII fraction 60.Oml was applied to a RESOUR SES column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer A, and dissolved with a linear gradient of 0 to 50 OmM NaC1 using FPLC system. RNase HII fraction eluted at about 15 OmM NaC1 was obtained. This RNase HII fraction (2.0 ml) was concentrated by ultrafiltration using Centricon-1 10 (Millipore).
- the RNaseHII eluted in this manner was used as a PfuRNaseHII standard.
- the enzyme activity was measured by the method described in Example 3_ (5) using the P iu RNase H II sample obtained above, and as a result, RNase H activity was observed in the P fu RNase HII sample. Admitted.
- oligonucleotide 915—F based on the nucleotide sequence of the portion identified as the RNaseHII gene 1 (SEQ ID NO: 24), 915-F2 (SEQ ID NO: 25), 915-R1 (SEQ ID NO: 26) and 915-R2 (SEQ ID NO: 27) were synthesized.
- 915—F1 and 915—R1, 915—F1 and 915—R2, 915—F2 and 915—R1 were used as a primer pair, and PCR was performed for each.
- the DNA polymerase used in the PCR was Takara Ex tack (Takara Shuzo Co., Ltd.) according to the attached protocol, and the PCR was performed at 95 ° C for 0.5 minutes, at 55 ° C for 0.5 minutes, and at 72 ° C for 1.5 minutes. Each cycle was performed for 25 cycles. After completion of the reaction, each PCR reaction product was subjected to agarose gel electrophoresis, and an amplified DNA fragment of about 0.7 kb was extracted and purified.
- the DNA amplified with the primer pairs 915-F2 and 915-R1 and 915-F2 and 915-R2 was double-digested with NcoI (Takara Shuzo) and XbaI.
- PTV119N manufactured by Takara Shuzo
- I and XbaI was ligated with T4 DNA ligase to transform Escherichia coli JM109.
- This transformant was cultured to prepare a plasmid DNA into which a DNA fragment of about 0.7 kb was inserted.
- a plasmid No. 7 containing the amplified DNA was obtained.
- Escherichia coli JM109 transformed with plasmid Nos. 1 to 7 or pUC19 was used in 5 ml LB medium containing 100 ⁇ g / m1 ampicillin (tryptone 10 gZ1, yeast extract 5 g / l, NaCl5 g / ⁇ 7.2) and cultured with shaking at 37 ° C.
- tryptone 10 gZ1, yeast extract 5 g / l, NaCl5 g / ⁇ 7.2 100 ⁇ g / m1 ampicillin
- yeast extract 5 g / l yeast extract 5 g / l, NaCl5 g / ⁇ 7.2
- the cells were cultured with shaking for 1 ⁇ . After completion of the culture, the cells were collected by centrifugation, suspended in 1 ml of TE buffer, and sonicated. This was heat-treated at 80 for 10 minutes, and the supernatant obtained by centrifugation was used as a crude cell extract.
- the absorbance was measured by the method described in Example 2- (5) using the obtained crude cell extract.
- nucleotide sequence of the DNA fragment inserted into the plasmid which was found to express RNaseH activity in E. coli, was determined.
- SEQ ID NO: 58 The nucleotide sequence of this open reading frame is shown as SEQ ID NO: 58 in the sequence listing.
- amino acid sequence of 1 I is shown in SEQ ID NO: 59 in the sequence listing.
- base sequence of the DNA fragment inserted into this plasmid No. 7 one base substitution which was considered to have occurred at the time of PCR was found, and it was found that the amino acid residue at that position was changed.
- Example 5 Escherichia coli JM109 was transformed with plasmid No. 7 (plasmid pTM-RNH) obtained in (2), and Escherichia coli JM109 containing pTM-RNH obtained was treated with 100 gZm1 of ampicillin.
- the cells were inoculated into 11 LB medium containing E. coli and cultured with shaking at 37 ° C for 16 hours.
- Sony cable Chillon buffer [50mM Tris-HC 1 of 31. 0 m 1
- the bacterial cells were collected by centrifugation (p H 8. 0), 2 mM 2- mercaptoethanol, 10% Guriseronore, 2mM phenylene Noremetan Sulfonyl fluoride] and sonicated. This crushed liquid 1
- PD_10 column (Amersham Pharmacia Biotech, Inc.) equilibrated with 2.0 ml of this RNase HII fraction with buffer C containing 50 mM NaCl. 3.5 mL of the obtained eluate was subjected to Hi Trap—he ⁇ arin column (Amersham Fanoremasa Biotech), which had been post-purified with buffer C containing 50 mM NaCl, and subjected to FPLC. Elution was carried out with a 50-55 OmM NaCl linear gradient using the system. As a result, an RNaseHII fraction eluted at about 295 mM NaCl was obtained.
- RNAse HII eluted in this manner was used as a TmaRNase HII standard.
- the obtained cells were suspended in 4 ml of 25% sucrose, 50 mM Tris-HC1 (H 8.0), and 0.4 ml of 1 OmgZm1 lysozyme chloride (manufactured by Nacalai Tesque) 7) The solution was added and reacted at 20 ° C for 1 hour.
- Example 6 The nucleotide sequence of the inserted DNA fragment of pPHO238 obtained in (2) was determined by the dideoxy method.
- SEQ ID NO: 31 in SEQ ID NO: 31 shows the nucleotide sequence of ' Also, from the base sequence The deduced amino acid sequence of RNase HII is shown in SEQ ID NO: 32 in the sequence listing.
- E. coli JM 109 transformed with plasmid P PH0238 is named Escherichia coli JM109 / pPH023 8, is displayed, 2001 February 22 (original deposit date) than S home country ⁇ 305- 8566, Tsukuba, Ibaraki It has been deposited with the Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology under the accession number FE RM BP—7692.
- Example 6 Escherichia coli HMS 174 (DE3) (manufactured by Novagen) was transformed with pPHO238 obtained in (2), and Escherichia coli HMS174 (DE3) containing the obtained pPHO238 was transformed into 100 cells.
- the cells were inoculated into 11 LB medium containing ⁇ gZmI of ampicillin, and cultured with shaking at 37 ° C. for 16 hours. After completion of the culture, the cells collected by centrifugation were suspended in 34.3 ml of a sonication buffer [5 OmM Tris-HC1 (pH 8.0), 1 mM EDTA, 2 mM phenylmethanesulfonyl fluoride].
- the heat-treated supernatant was applied to a RES OUR SEQ column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer A [5 OmM Tris_HC1 (pH 8.0), ImM EDTA], and the FP LC system (Amersham Pharmacia Biotech) was used. (Manufactured by KK). As a result, RNase HII passed through the RESOURSE Q column.
- the RNaseHI fraction 35.Oml passed through was dialyzed for 2 hours three times using 2 L of buffer B [5 OmM Tris-HC1 (pH 7.0) and ImM EDTA] as an external solution. 34.5 ml of the enzyme solution after dialysis is applied to a RESOURSE S column (Pharmacia Biotechnology, Inc.) equilibrated with buffer B, and eluted with a linear gradient of 0 to 50 OmM NaCl using an FP LC system. Then, an RNaseHII fraction eluted at about 155 mM NaCl was obtained. This fraction 4.
- the RNaseHII fraction (6.9 m1) was concentrated by ultrafiltration using Centricon-10 (Millipore), and concentrated at 25 ⁇ ⁇ ⁇ 2 nights into 10 OmM. NaCl, 0.
- the sample was applied to a Superose 6 gel filtration column (manufactured by Amersham Pharmacia Biotech) equilibrated with 5 OmM Tris-HC1 (H7.0) containing ImM EDTA, and eluted with the same buffer.
- RNaseHII eluted at a position corresponding to a molecular weight of 24.5 kilodaltons. This molecular weight corresponds to the case where RNase HII is present as a monomer.
- the RNaseHII eluted in this manner was used as a PhRNaseHII standard.
- the enzyme activity was measured by the method described in Example 3- (5) .As a result, RNaseH activity was observed in the PhRNase HII sample. Was done.
- Archaeoglobus fulgidus (Purchased from Germany, Chezamnolenk von Mikrio ⁇ / Gaesmenwent Zertanoretren Gmb H: D SM41 39) Collect 8 m1 equivalent of cells, 100 1 25% sucrose, Suspend in Tris «[ ⁇ 1 (pH 8.0), add 20 1 0.5M EDTA, 10 / z 1 1 OmgZm 1 lysozyme chloride (manufactured by Nacalai Tester), add water solution, and add The reaction was performed for 1 hour.
- primers AfuNde (SEQ ID NO: 34) and AfuBam (SEQ ID NO: 35) were synthesized based on the sequence of the AF0621 gene (SEQ ID NO: 33).
- Example 7 Alkaeoglobus fulgidas 3 Ong obtained in (1) was transformed into type III, and AfuN de of 20 pmo 1 and AfuBam of 20 pmo 1 were used as primers to obtain 100 1 PCR was performed with the following volume.
- DNA polymerase in PCR use pi-Vest DNA polymerase (Takara Shuzo) according to the attached protocol.PCR was performed for 30 seconds at 94 ° C, 30 seconds at 55 ° C, and 1 minute at 72 ° C.
- the amplified DNA fragment of about 0.6 kb was digested with Nde I and BamHI (both from Takara Shuzo), and the obtained DNA fragment was digested with plasmid vector pTV1 19Nd (NcoI site of pTVl 19N). Plasmid integrated between NdeI and BamHI of NdeI site) ) AFU204 was prepared.
- the nucleotide sequence of the inserted DNA fragment of pAFU204 obtained in Example 7_ (2) was determined by the dideoxy method.
- E. coli JM109 was transformed with pAFU204 obtained in Example 7- (2) and obtained: E. coli JMl09 containing AFU204 was inoculated into 21 LB medium containing 100 g / ml ampicillin And cultured with shaking at 37 for 16 hours. After completion of the culture, the cells collected by centrifugation were placed in 37.lm1 sonication buffer [5 OmM Tris-HC1 (pH 8.0), 1 mM EDTA, 2 mM phenyl methanesulfur fluoride]. Suspended and sonicated
- 37.lm1 sonication buffer [5 Om
- the heat-treated supernatant was applied to a RES OUR SEQ column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer A [5 OmM Tris-HC1 (pH 8.0), ImM EDTA], and the FP LC system (Amersham Pharmacia Biotech) was used. (Manufactured by KK). As a result, RNase HII passed through the RE SOUR SEQU column.
- RNAseHI I passed through the RESOURSE S column.
- the RNase HII fraction (7.8 ml) was concentrated by ultrafiltration using Centricon 10 (manufactured by Millipore), and about 600 ⁇ l of the concentrated solution was divided into four portions to obtain 10 OmM Na Cl, 0.
- the solution was applied to a Superose 6 gel filtration column (manufactured by Amersham Pharmacia Biotech) equilibrated with 5 OmM Tris_HC1 (pH 7.0) containing ImM EDTA, and eluted with the same buffer.
- ase HII was eluted at a position corresponding to a molecular weight of 30.0 kilodaltons. This molecular weight corresponds to the case where RNase HII exists as a monomer.
- the RNase HEI I eluted in this manner was used as an AfuRNase HI I preparation.
- the enzyme activity was measured by the method described in Example 3- (5), and as a result, the AfuRNase HII sample showed RNase H activity The student was recognized.
- Thermococcus litoralis Collected 1 lm 1 equivalent of cells, and 5 0 1 2 5% Sugar, suspended in 50 mM Tris-HC1 (pH 8.0), added 1001 of 0.5 M EDTA, 50 ⁇ l of 1 Omg / m1 lysozyme chloride (manufactured by Nacalai Tester), and added an aqueous solution. The reaction was carried out at ° C for 1 hour.
- Oligonucleotides RN—F1 (SEQ ID NO: 38) and RN-RO (SEQ ID NO: 39) were synthesized based on the conserved portions between the amino acid sequences of various heat-resistant RNase HIIs. Synthesized. Using the Thermococcus littoralis genomic DNA solution 5 / z1 prepared in Example 8 (1) above as a type III, using 100 pmo1 of RN-F1 and 100 pmo1 of RN-R0 as primers, PCR was performed with a volume of ⁇ 1.
- the DNA polymerase used in the PCR was Takara Tack (Takara Shuzo Co., Ltd.) according to the attached protocol.
- the PCR was performed at 94 ° C for 30 seconds, 45 ° C for 30 seconds, and 72 ° C for 1 minute as one cycle. 50 cycles were performed.
- the primer was removed and concentrated simultaneously using Microcon 100 (manufactured by Takara Shuzo).
- Example 8 Determining the nucleotide sequence of the fragment T 1i F 1RO of about 0.5 kb obtained in (2) above, a specific oligonucleotide T 1 i for upstream cloning based on it.
- RN-1 SEQ ID NO: 40
- a specific oligonucleotide Tli RN-2 SEQ ID NO: 41
- 48 types of primers shown in Table 1 were synthesized.
- the tag sequence in Table 1 is shown in SEQ ID NO: 60 in the sequence listing.
- Example 8 1 ⁇ l of Thermococcus littoralis genomic DNA solution prepared in (1) was type- ⁇ , and 20 pmo-1 ⁇ 1 iRN—1 or 20 pmo1 T1iRN—2 2 OmM tris acetic acid ( ⁇ 8.5), 50 mM potassium acetate, 3 mM magnesium acetate, 0.01% BSA, 30 M dNTP mixture for each, Perform PCR in a reaction solution containing 5 units of Takara ExTaq DNA polymerase (Takara Shuzo). became.
- PCR was performed for 40 cycles, with 10 cycles at 98 ° C, 10 seconds at 50 ° C, and 40 seconds at 72.
- a portion of the obtained PCR product was electrophoresed through agarose, and a single band was selected.
- the reaction solution was concentrated using Microcon 100 (manufactured by Takara Shuzo) while removing the primers. Then, a direct sequence was performed to screen for a fragment containing the upstream or downstream of RNaseHII.
- the upstream of the RNaseHII gene was about 600 bp of the ⁇ 1 amplified fragment 1 iC25, and about 400 b ⁇ of the PCR amplified fragment T1iC26. was found to contain downstream flow.
- the nucleotide sequence of the gene containing T1iRNaseHII is shown in SEQ ID NO: 42 in the sequence listing.
- the amino acid sequence of RNaseHII deduced from the nucleotide sequence is shown in SEQ ID NO: 43 of the sequence listing.
- primers T1iNde (SEQ ID NO: 44) and T1iBam (SEQ ID NO: 45) were synthesized.
- Example 8 1 ⁇ m of the Thermococcus littoralis genomic DNA solution obtained in (1)
- PCR was performed in a volume of 100 ⁇ l using 1 as a ⁇ and using T 1 iNde of 20 pmo 1 and TliBam of 2 O pmol as primers.
- EXT aq DNA polymerase (Takara Shuzo Co., Ltd.) was used as the DNA polymerase in the PCR according to the attached protocol. The PCR was performed at 94 ° C for 30 seconds, 55 ° C for 30 seconds, and 72 ° C for 1 minute. Went 40 cycling. Approximately 0.7 kb of amplified DNA fragment
- Plasmids: TLI223Nd and pTLI204 were prepared by integrating pET3a (manufactured by Novagen) between Ndel and BamHI.
- Example 8 The nucleotide sequences of the inserted DNA fragments of pTLI223Nd and pTLI204 obtained in (4) were determined by the dideoxy method.
- RNaseHII was encoded.
- a possible open reading frame was found.
- the nucleotide sequence of the open reading frame of pTL I204 is shown in SEQ ID NO: 46 in the Sequence Listing.
- the amino acid sequence of RNaseHII deduced from the nucleotide sequence is shown in SEQ ID NO: 4 in the Sequence Listing. It is shown in 7.
- the nucleotide sequence of the open reading frame of TLI 223Nd was such that the T at position 484 was replaced by C compared to pTL I 204.
- the phenylalanine at position 162 was found in the amino acid sequence.
- Escherichia coli HMS 174 (DE 3) transformed with the plasmid; TLI 204 was named and displayed as Escherichia coli HMS 174 (DE 3) / pTLI204, and was identified as February 22, 2001.
- Escherichia coli JM109 transformed with pTLI223Nd was inoculated into 10 ml LB medium containing 100 / ig / ml ampicillin and ImMIPTG, and cultured at 37 ° C with shaking for 1 °. After completion of the culture, the cells collected by centrifugation were
- Example 8 E. Coli JM109 was transformed with pTLI223Nd obtained in (4), and E. coli JM109 containing pTLI223Nd was obtained at 100 g / m 1.
- E. coli JM109 containing pTLI223Nd was obtained at 100 g / m 1.
- This crushed liquid was centrifuged at 12000 rpm for 10 minutes, and the obtained supernatant was subjected to a heat treatment at 70 ° C. for 15 minutes. Then, centrifugation was again performed at 12000 rpm for 20 minutes, and the supernatant was collected to obtain a heat treated supernatant of 37.2 ml.
- Buffer A was added to 3 ml of this RNase HII fraction so that the NaC1 concentration was 5 OmM, and a HiTraph eparin column (Amersham) equilibrated with buffer A containing 5 OmM NaC1. (Pharmacia Biotech) and eluted with a linear concentration gradient of 50 to 55 OmM NaC1 using an FP LC system. As a result, an RNase HII fraction eluted at about 320 mM NaCl was obtained.
- the RNase HII fraction (6 ml) was concentrated by ultrafiltration using Centricon 10 (manufactured by Millipore), and about 198 ⁇ l of the concentrated solution was added to 10 OmM NaCl, 0.1 mL.
- T 1 i RNa S eHI I preparation obtained above, a result of measuring the enzyme activity according to the method of mounting the serial in Example 3- (5), T 1 i RNa s eHI I preparation in RNa s eH activity was observed.
- Thermococcus celer purchased from Die Zerkrutzlen GmbH, Germany
- Oligonucleotides RN-F1 SEQ ID NO: 48
- oligonucleotide RN-R0 SEQ ID NO: 49
- PCR was performed with a volume of 1.
- the DNA polymerase used in the PCR was Takara Tack (Takara Shuzo) according to the attached protocol. The PCR was performed at 94 ° C for 30 seconds, 45 ° C for 30 seconds, and 72 ° C for 1 minute. I went 50 cycling.
- the amplified DNA fragment of about 500 bp was blunt-ended using T4 DNA polymerase (manufactured by Takara Shuzo Co., Ltd.), followed by agarose gel electrophoresis, and the amplified DNA fragment of about 500 bp Was recovered.
- the obtained approximately 500 bp pDNA fragment was ligated to pUC119 (Takara Shuzo) digested with Smal (Takara Shuzo) using T4 DNA ligase (Takara Shuzo) to ligate E. coli JM109. Transformation.
- the transformant was cultured to obtain a plasmid pTceF1R0 into which a DNA fragment of about 500 bp was inserted.
- the nucleotide sequence of the plasmid pTceFIRO obtained in Example 9- (2) above was determined, and a specific oligonucleotide TceRN-1 (cloning sequence No. 50) for upstream cloning was determined based on the nucleotide sequence. ) And a specific oligonucleotide TceRN_2 (SEQ ID NO: 51) for downstream downstream synthesis.
- Example 9 The Thermococcus cellar genomic DNA solution 1 / i1 prepared in (1) was made into a zigzag form, and 20 pmo 1 T 1 i RN—1 or 20 pmo 1 T 1 i RN—2 and 20 pmo each 1 of 48 primers (example 8 shown in table 1) combination with at 2 Omm tris acetate (pH 8. 5), 50mM potassium acetate, 3 mM magnesium acetate, 0. 01 0/0 ⁇ SA , each 30 PCR was performed in a reaction mixture containing the / iMdNTP mixture and 2.5 units of Takara EXT aq DNA polymerase (Takara Shuzo).
- PCR was incubated at 94 ° C for 3 minutes, then at 98 ° C for 10 seconds, at 50 ° C for 10 seconds, 72. The cycle was 40 seconds in C for 40 seconds.
- Single-banded PCR products were selected from the obtained PCR products, and the reaction solutions were concentrated with Microcon 100 (manufactured by Takara Shuzo Co., Ltd.) at the same time as removing the primers, followed by direct sequencing, and RNaseHI I Fragments containing upstream or downstream were screened.
- Microcon 100 manufactured by Takara Shuzo Co., Ltd.
- the nucleotide sequence of the gene containing TcRNaseSeHII is shown in SEQ ID NO: 52 in the sequence listing.
- the amino acid sequence of RNaseHII deduced from the nucleotide sequence is shown in SEQ ID NO: 53 of the sequence listing.
- primers TceNde (SEQ ID NO: 54) and TceBam (SEQ ID NO: 55) were synthesized.
- Example 9 The Thermococcus cellar genomic DNA solution ( ⁇ ) obtained in (1) was used as a type II, and 20 pmol of TceNde and 20 pmo1 of TceBam were used as primers. PCR was performed in one volume. For DNA polymerase in PCR, pi-Vest DNA polymerase (Takara Shuzo) was used according to the attached protocol.PCR was carried out for 30 seconds at 94 ° C, 30 seconds at 55 ° C, and 1 minute at 72 ° C. 1 The cycle was 40 cycles.
- the amplified DNA fragment of about 0.7 kb was digested with NdeI and BamHI (both from Takara Shuzo Co., Ltd.), and the resulting DNA fragment was added to a plasmid vector; pTV119Nd (NcoI of pTV119N).
- the site was converted to an NdeI site) or pET3a (manufactured by Novagen) was inserted between Ndel and BamHI to prepare plasmids: TCE265Nd and pTCE207.
- Example 9 obtained in (4); The nucleotide sequence of the inserted DNA fragment of TCE 265Nd and pTCE207 was determined by the dideoxy method.
- nucleotide sequence of the open reading frame of pTCE207 is shown as SEQ ID NO: 56 in the sequence listing.
- amino acid sequence of RNaseHII deduced from the nucleotide sequence is shown in SEQ ID NO: 57 in the sequence listing.
- the 14th A is replaced by G compared to p TCE 207, and
- the 96th was deleted.
- glutamic acid at position 5 has been replaced by dalysin, and 231 at phenylalanine has been deleted.
- Escherichia coli HMS 174 (DE 3) transformed with the plasmid PTCE207 was named and indicated as Escherichia coli HMS 174 (DE 3) / pTCE207, and was filed on February 22, 2001 (Hara Deposit 3).
- Escherichia coli JM109 transformed with TCE265Nd was inoculated into 10 ml of LB medium containing 100 / ig / m1 of ampicillin and ImM I PTG.
- the cells were cultured at 7 ° C with shaking for 1 °. After completion of the culture, the cells collected by centrifugation were suspended in 203 ⁇ l of buffer ⁇ and sonicated. This crushed liquid was centrifuged at 12000 rpm for 10 minutes, and the obtained supernatant was subjected to a heat treatment at 70 ° C for 10 minutes. After that, centrifuge again at 12000 rpm for 10 minutes, collect the supernatant, A heat-treated supernatant was obtained. Similarly, Escherichia coli HMS174 (DE3) transformed with pTCE207 was inoculated into 1 Om1 LB medium containing 100 ⁇ g Zm1 ampicillin, and cultured at 37 ° C for 1 hour with shaking. The cells collected by centrifugation were treated in the manner described above to obtain a heat-treated supernatant.
- E. coli JM109 was transformed with the pTCE 265Nd obtained in Example 9_ (4), and the obtained E. coli JMl09 containing pTCE 265Nd was inoculated into 21 LB medium containing 100 g / m1 ampicillin.
- the cells were cultured with shaking at 37 for 16 hours. After completion of the culture, the cells collected by centrifugation are suspended in 39 ml of sonication buffer [5 OmM Tris-HC1 (pH 8.0), 1 mM EDTA, 2 mM phenylmethanesulfonyl fluoride], and sonicated. On the machine.
- This crushed liquid was centrifuged at 12000 r111 for 10 minutes, and the obtained supernatant was subjected to a heat treatment at 70 ° C for 15 minutes. Thereafter, centrifugation was again performed at 12000 rpm for 20 minutes, and the supernatant was collected to obtain a heat-treated supernatant of 37.5 ml.
- the heat-treated supernatant was applied to a RES OU RSEQ column (manufactured by Amersham Pharmacia Biotech) equilibrated with buffer A [5 OmM Tris-HC1 (pH 8.0), ImM EDTA], and subjected to an F PLC system (Amersham Pharmacia). Chromatography was performed using Biotech). As a result, RNase HII passed through the RESOURSE Q column.
- the RNase HII fraction 3 ml was backed up to a NaC1 concentration of 5 OmM.
- F-A was added, and the mixture was applied to a Hi Traph eparin column (manufactured by Amersham Fanolemasia Biotech) equilibrated with buffer-A containing 50 mM NaC1, and the FPLC system was used to provide 50 to 55 OmM Na. It was eluted by a C1 linear concentration gradient. As a result, an RNase HII fraction eluted at about 415 mM NaC1 was obtained.
- BCA Bacillus cardotenax
- PFU Pyrococcus furiosas
- TMA Thermotoga maritima
- AFU Arcaeoglobus fulgidas
- TL Thermococcus li tralis
- the homology of the amino acid sequences of PH ⁇ , AFU, TLI, and TCE to PFU was 69%, 45%, 65%, 58%, and the homology of the nucleotide sequence was 68%, 60 °, respectively, based on DNASIS. /. , 65% and 61%.
- the gene database was searched for PHO, AFU, and TMA using the computer algorithm FAS TA.
- the amino acid sequence predicted to be liponuclease has the highest homology to the PHO amino acid sequence at 70 ° / 0 , and the lowest homology has 20% homology to the PHO amino acid sequence.
- a substrate was prepared as follows in order to compare the cleavage modes of BcaRNaseHIII and E.coliRNaseHI. 5'-end FITC-labeled chimeric primer VT 2—R 28 ON3-I 7 (SEQ ID NO: 61) and DNA primer VT 2—F 110 (SEQ ID NO:
- PCR was performed using the method of (62) to obtain a DNA fragment containing three RNAs in one of the two strands.
- the primer was removed from the PCR product using Microcon 100 (manufactured by Millipore) and used as a substrate for cleavage with RNaseH.
- Example 3 coli RNaseHI 3 OU / ⁇ 1 (Takara Shuzo) or Bca RNaseHII II purified sample obtained in Example 3 (5) was diluted 10-fold with buffer A. The solution was weighed 0.8 calories and reacted at 55 ° C for 5 minutes and 10 minutes. After the reaction, 2 ⁇ l of the reaction solution was electrophoresed on a 10% denaturing acrylamide gel to confirm the size of the cleaved DN ⁇ fragment.
- E.co1iRNaseHI was cleaved between two RNAs. It is also considered that after cleaving the 5 'side of the 3' RNA, the RNA has the activity of further cleaving the 5 'side of the 3' RNA without binding to the DNA.
- BcaRNaseHIII cuts only the 5 ′ side of the 3 ′ RNA, and does not cut when DNA is not bound to the 3 ′ side of the RNA. It is considered that the selectivity of the cleavage position is higher than that of E. coli RNaseHI.
- Substrates were prepared as follows in order to analyze the cleavage modes of Rfu of Pfu (Pyrococcus furiosus), Pho (Pyrococcus horikoshi), and Afu (Arcaeoglobus fulgidas).
- Escherichia coli O157 heat extract was type III, 5'-end FITC-labeled chimeric primer with 3 bases RNA from the 3 'end VT2-IF20N3 (SEQ ID NO: 63), 5'-end FITC labeled chimera primer with 2 bases RNA VT 2—IF 19N2 (SEQ ID NO: 64), 5′-end FITC-labeled chimeric primer with one base RNA VT 2—IF 18N 1 (SEQ ID NO: 65) and DNA primer VT 2 IR 20 (SEQ ID NO: 66) Perform PCR using DNA fragments, VFN3, VFN2, and VFN1, containing three, two, or one RNA in one strand of the main strand were obtained. The primers were removed from these PCR products using Microcon 100, and used as substrates for cleavage with RNaseH.
- VFN3 When VFN3 was used as a substrate, a signal was obtained at the position of 19 base with respect to RNaseHI of Pfu, Pho, and Afu.
- VFN2 When VFN2 was used as a substrate, Pfu, Pho, A signal was obtained at 18 bases for RNaseHII of Afu, and a signal was obtained at 17 bases for RNaseHII of Pfu and Pho when VFN1 was used as a substrate. .
- RNaseHII of Pfu, Pho, and Afu cut the 3'-side RNA at the 5 'side.
- RNase HII of Pfu and Pho cut the 5 'side of RNA even with one RNA.
- RNaseH which cuts at least one RNA, has not been reported.
- the signal intensity in the case of cleavage was similar regardless of the number of RNAs, indicating that there was no difference in the cleavage efficiency depending on the number of RNAs.
- Reaction buffer containing substrate 0.3 pmo 1 (2 OmM Hepes-KOH ( pH 7.8), 1% dimethyl sulfoxide, 0.01% serum albumin, lOOmM potassium acetate, 4mM magnesium acetate, 0.002% propylenediamine) 39.2 1 and substrate 0.3 Mn + reaction buffer containing pmo 1 (20 mM Hepes-KOH (pH 7.8), 1% dimethinoresnorole foxoxide, 0.0 1% ⁇ serum albumin, lO OmM potassium acetate, 1
- OmM manganese chloride, 0.002% propylenediamine) 39.2 ⁇ l was prepared.
- E. coli RNaseHI3 ⁇ / ⁇ 1 (Takara Shuzo) or Bca RNaseHII purified sample obtained in Example 2 (6) Add 0.8 ⁇ l of a 1: 2 diluted solution or a solution obtained by diluting the Tma RNase HII bacterial cell crude extract obtained in step ⁇ J5— (3) 25-fold with buffer A at a temperature of 55 ° C. For 5 minutes and 10 minutes. After the reaction, 2/1 of the reaction solution was electrophoresed on a 10% denaturing acrylamide gel to confirm the size of the cleaved DNA fragment.
- Example 1 RN ase H activity assay B in M g 2+ presence at all no activity in ea RNa s eH II and Tma RN ase HII showed comparable cleavage activity in the case of Mn 2 +.
- the present invention provides a polypeptide having RNaseH activity, which is highly useful in genetic engineering, a gene encoding the polypeptide, and a method for producing the polypeptide by genetic engineering. Further, the RNaseH of the present invention has heat resistance, and an industrially advantageous method for producing RNaseH is also provided.
- the present invention makes it possible to use the RNaseH of the present invention in various applications. Sequence listing free text
- SEQ ID NO: 1 PCR primer BsuII-3 for cloning a gene encoding a polypeptide having a RNaseHII activity from Bacillus caldotenax.
- SEQ ID NO: 2 PCR primer BsuII-6 for cloning a gene encoding a polypeptide having a RNaseHII activity from Bacillus caldotenax.
- SEQ ID NO: 3 PCR primer thigh I SI for cloning a gene encoding a polypeptide having a RNaseHII activity from Bacillus caldotenax.
- SEQ ID NO: 4 PCR primer RNII-S2 for cloning a gene encoding a polypeptide having a RNaseHII activity from Bacillus caldotenax.
- SEQ ID NO: 5 PCR primer ⁇ I— S5 for cloning a gene encoding a polypeptide having a RNaseHII activity from Bacillus caldotenax.
- SEQ ID NO: 6 PCR primer R II-S6 for cloning a gene encoding a polypeptide having a RNaseHII activity from Bacillus caldotenax.
- SEQ ID NO: 7 PCR primer ⁇ 1— Nde for cloning a gene encoding a polypeptide having a RNaseHII activity from Bacillus caldotenax.
- SEQ ID NO: 10 PCR primer BsuIII- 1 for cloning a gene encoding a polypeptide having a RNaseHIII activity from Bacillus caldotenax.
- SEQ ID NO: 11 PCR primer BsuIII-3 for cloning a gene encoding a polypeptide having a RNaseHIII activity from Bacillus caldotenax.
- SEQ ID NO: 12 PCR primer BsuIII-6 for cloning a gene encoding a polypeptide having a RNaseHIII activity from Bacillus caldotenax.
- SEQ ID NO: 13 PCR primer BsuIII-8 for cloning a gene encoding a polypeptide having a RNaseHIII activity from Bacillus caldotenax.
- SEQ ID NO: 14 PCR primer RNIII— S3 for cloning a gene encoding a.polypeptide having a RNaseHIII activity from Bacillus caldotenax.
- SEQ ID NO: 15 PCR primer BcaRNIII-3 for cloning a gene encoding a polypeptide having a RNaseHIII activity from Bacillus caldotenax.
- SEQ ID NO: 18 PCR primer BcaRNIIINde for amplifying a gene encoding a polypeptide having a RNaseHIII activity from Bacillus caldotenax.
- SEQ ID NO: 20 PCR primer 1650Nde for cloning a gene encoding a polypeptide having a RNaseHII activity from Pyrococcus furiosus.
- SEQ ID NO: 21 PCR primer 1650Bam for cloning a gene encoding a polypeptide having a RNaseHII activity from Pyrococcus furiosus.
- SEQ ID NO: 24 PCR primer 915-Fl for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermotoga maritima.
- SEQ ID NO: 25 PCR primer 915-F2 for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermotoga maritime.
- SEQ ID NO: 26 PCR primer 915— Rl for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermotoga maritima.
- SEQ ID NO: 27 PCR primer 915-R2 for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermotoga maritima.
- SEQ ID NO: 29 PCR primer PhoNde for cloning a gene encoding a polypeptide having a RNaseHII activity from Pyrococcus horikoshii.
- SEQ ID NO: 30 PCR primer PhoBam for cloning a gene encoding a polypeptide having a RNaseHII activity from Pyrococcus horikosnii.
- SEQ ID NO: 34 PCR primer AfuNde for cloning a gene encoding a polypeptide having a RNaseHII activity from Archaeoglobus fulgidus.
- SEQ ID NO: 35 PCR primer AfuBam for cloning a gene encoding a polypeptide having a RNaseHII activity from Archaeoglobus fulgidus.
- SEQ ID NO: 38 PCR primer RN-Fl for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus litoralis.
- SEQ ID NO: 39 PCR primer RN-RO for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus litoralis.
- SEQ ID NO: 0 PCR primer TliRN-1 for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus litoralis.
- SEQ ID NO: 41 PCR primer TliRN- 2 for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus litoralis.
- SEQ ID N0: 44 PCR primer TliNde for amplifying a gene encoding a polypeptide having a RNaseHII activity from Thermococcus litoralis.
- SEQ ID NO: 45 PCR primer TliBam for amplifying a gene encoding a polypeptide having a RNaseHIII activity from Thermococcus litoralis.
- SEQ ID NO: 48 PCR primer RN-Fl for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus celer.
- SEQ ID NO: 49 PCR primer RN-RO for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus celer.
- SEQ ID NO: 50 PCR primer TceRN-1 for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus celer.
- SEQ ID NO: 51 PCR primer TceRN-2 for cloning a gene encoding a polypeptide having a RNaseHII activity from Thermococcus celer.
- SEQ ID NO: 54 PCR primer TceNde for amplifying a gene encoding a polypeptide having a RNaseHII activity from Thermococcus celer.
- SEQ ID NO: 55 PCR primer TceBam for amplifying a gene encoding a polypeptide having a RNaseHIII activity from Thermococcus celer,
- SEQ ID NO: 61 Designed chimeric oligonucleotide primer as VT2-R280N3- I 7 for amplifying a portion of vero toxin 2-encoding sequence from hemorr hagic Escherichia coli 0-157. "Nucleotides 18 to 20 are ribonucleotides-o ther nucleotides are deoxyribonucleotides
- SEQ ID NO: 62 Designed oligonucleotide primer as VT2-F110 for amplifying a portion of vero toxin 2-encoding sequence from hemorrhagic Escheric hia coli 0-157.
- SEQ ID NO: 63 Designed chimeric oligonucleotide primer as VT2-IF20N3 for or amplifying a VFN3 from hemorrhagic Escherichia coli 0-157. "Nucleotides 17 to 19 are ribonucleotides-o ther nucleotides are deoxyribonucleotide s
- SEQ ID N0: 64 Designed chimeric oligonucleotide primer as VT2-IF19N2 for or amplifying VFN2 from hemorrhagic Escherichia coli 0-157. "Nucleotides 16 to 18 are ribonucleotides-other nucleotides are deoxyribonucleotides"
- SEQ ID NO: 65 Designed chimeric oligonucleotide primer as VT2-IF18N1 for or amplifying a VFNl from hemorrhagic Escherichia coli 0-157, "Nucleotides 15 to 17 are ribonucleotides— other nucleotides are deoxyribonucleotide s
- SEQ ID NO: 66 Designed oligonucleotide primer as VT21R20 for amplifyin g a portion of vero toxin 2— encoding sequence from hemorrhagic Escherich ia coli 0—157.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Magnetic Ceramics (AREA)
- Treatment Of Sludge (AREA)
- Detection And Prevention Of Errors In Transmission (AREA)
- Error Detection And Correction (AREA)
- Measurement Of Force In General (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60136198T DE60136198D1 (en) | 2000-09-14 | 2001-09-13 | Thermotolerante ribonuklease h |
AU2001286211A AU2001286211A1 (en) | 2000-09-14 | 2001-09-13 | Thermotolerant ribonuclease h |
US10/380,430 US7422888B2 (en) | 2000-09-14 | 2001-09-13 | Thermotolerant ribonuclease H |
JP2002527273A JP3910142B2 (ja) | 2000-09-14 | 2001-09-13 | 耐熱性リボヌクレアーゼh |
KR1020037003322A KR100578476B1 (ko) | 2000-09-14 | 2001-09-13 | 내열성 리보뉴클레아제 h |
EP01965599A EP1318197B1 (en) | 2000-09-14 | 2001-09-13 | Thermotolerant ribonuclease h |
US12/194,364 US8008055B2 (en) | 2000-09-14 | 2008-08-19 | Thermotolerant ribonuclease H |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000280785 | 2000-09-14 | ||
JP2000-280785 | 2000-09-14 | ||
JP2001064074 | 2001-03-07 | ||
JP2001-64074 | 2001-03-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10380430 A-371-Of-International | 2001-09-13 | ||
US12/194,364 Division US8008055B2 (en) | 2000-09-14 | 2008-08-19 | Thermotolerant ribonuclease H |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002022831A1 true WO2002022831A1 (fr) | 2002-03-21 |
Family
ID=26600059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/007930 WO2002022831A1 (fr) | 2000-09-14 | 2001-09-13 | Ribonuclease h thermotolerant |
Country Status (10)
Country | Link |
---|---|
US (2) | US7422888B2 (ja) |
EP (2) | EP2009107A3 (ja) |
JP (1) | JP3910142B2 (ja) |
KR (2) | KR100696390B1 (ja) |
CN (1) | CN1250726C (ja) |
AT (1) | ATE411389T1 (ja) |
AU (1) | AU2001286211A1 (ja) |
DE (1) | DE60136198D1 (ja) |
TW (1) | TWI310404B (ja) |
WO (1) | WO2002022831A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020621A1 (ja) * | 2002-08-30 | 2004-03-11 | Takara Bio Inc. | 耐熱性リボヌクレアーゼh |
WO2010026933A1 (ja) | 2008-09-03 | 2010-03-11 | タカラバイオ株式会社 | Rna検出用組成物 |
WO2014142261A1 (ja) | 2013-03-14 | 2014-09-18 | タカラバイオ株式会社 | 耐熱性のミスマッチエンドヌクレアーゼの利用方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9434988B2 (en) | 2008-04-30 | 2016-09-06 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
EP3150727B1 (en) | 2008-04-30 | 2019-07-10 | Integrated DNA Technologies Inc. | Rnase-h-based assays utilizing modified rna monomers |
US8911948B2 (en) * | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
US8618253B2 (en) * | 2010-05-25 | 2013-12-31 | Samsung Techwin Co., Ltd. | Modified RNAse H and detection of nucleic acid amplification |
US9096984B2 (en) * | 2010-12-07 | 2015-08-04 | The Trustees Of Columbia University In The City Of New York | Network material devices, methods, and systems |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5610066A (en) * | 1993-12-10 | 1997-03-11 | Amersham Life Science, Inc. | Nucleic acid modifying proteins from Pyrococcus furiosus |
JPH1132772A (ja) * | 1997-07-24 | 1999-02-09 | Mitsubishi Chem Corp | 耐熱性リボヌクレアーゼh及びそれをコードするdna |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3909710A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur expression eines rekombinanten gens |
JP2533671B2 (ja) | 1990-04-26 | 1996-09-11 | 株式会社蛋白工学研究所 | 組換えdna技術による好熱菌リボヌクレア―ゼhの製造法 |
-
2001
- 2001-09-13 EP EP08013600A patent/EP2009107A3/en not_active Withdrawn
- 2001-09-13 AT AT01965599T patent/ATE411389T1/de not_active IP Right Cessation
- 2001-09-13 WO PCT/JP2001/007930 patent/WO2002022831A1/ja active IP Right Grant
- 2001-09-13 DE DE60136198T patent/DE60136198D1/de not_active Expired - Lifetime
- 2001-09-13 KR KR1020067005545A patent/KR100696390B1/ko not_active IP Right Cessation
- 2001-09-13 AU AU2001286211A patent/AU2001286211A1/en not_active Abandoned
- 2001-09-13 KR KR1020037003322A patent/KR100578476B1/ko not_active IP Right Cessation
- 2001-09-13 US US10/380,430 patent/US7422888B2/en not_active Expired - Lifetime
- 2001-09-13 CN CNB018186904A patent/CN1250726C/zh not_active Expired - Lifetime
- 2001-09-13 EP EP01965599A patent/EP1318197B1/en not_active Expired - Lifetime
- 2001-09-13 JP JP2002527273A patent/JP3910142B2/ja not_active Expired - Fee Related
- 2001-09-14 TW TW090122906A patent/TWI310404B/zh active
-
2008
- 2008-08-19 US US12/194,364 patent/US8008055B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5610066A (en) * | 1993-12-10 | 1997-03-11 | Amersham Life Science, Inc. | Nucleic acid modifying proteins from Pyrococcus furiosus |
JPH1132772A (ja) * | 1997-07-24 | 1999-02-09 | Mitsubishi Chem Corp | 耐熱性リボヌクレアーゼh及びそれをコードするdna |
Non-Patent Citations (10)
Title |
---|
DATABASE EMBL [online] 6 April 2000 (2000-04-06), Y. KAWARABAYASHI ET AL.: "Pyrococcus horikishii OT3 genomic DNA, 1166001-1485000 nt. position (6/7)", Database accession no. AP000006, Gene PH1650 * |
DATABASE GENBANK [online] 15 December 1997 (1997-12-15), H.-P. KLENK ET AL.: "Archaeoglobis fulgidus section 45 of 172 of the complete genome", accession no. NCBI Database accession no. AE001062 * |
DATABASE GENBANK [online] 2 June 1999 (1999-06-02), K.E. NELSON ET AL.: "Thermotoga maritima section 67 of 136 of the complete genome", Database accession no. AE001755, Gene TM0915 * |
DATABASE SWISSPROT [online] 30 May 2000 (2000-05-30), H.-P. KLENK ET AL.: "Ribonuclase HII (EC 3.1.26.4)", accession no. EMBL Database accession no. O29634 * |
DATABASE SWISSPROT [online] 30 May 2000 (2000-05-30), K.E. NELSON ET AL.: "Ribonuclease HII (EC 3.1.26.4)", Database accession no. Q9X017, Gene TM0915 * |
DATABASE SWISSPROT [online] 30 May 2000 (2000-05-30), Y. KAWARABAYASHI ET AL.: "Ribonuclease HII (EC 3.1.26.4)", Database accession no. 059351, Gene PH1650 * |
H.-P. KLENK ET AL.: "The Complete Genome Sequence of the Hyperthermophilic, Sulphate-reducing Archaeon Archaeoglobus Fulgidus", NATURE, vol. 390, no. 6665, 1997, pages 364 - 370, XP002088210 * |
K.E. NELSON ET AL.: "Evidence for lateral gene transfer between archaea and bacteria from genome sequence of thermotoga maritima", NATURE, vol. 399, no. 6734, 1999, pages 323 - 329, XP002937334 * |
M. HARUKI ET AL.: "Gene cloning and characterization of recombinant RNase HII from a hyperthermophilic aechaeon", J. BACTERIOL., vol. 180, no. 23, 1998, pages 6207 - 6214, XP002906359 * |
Y. YAWARABAYASHI ET AL.: "Complete sequence and gene organization of the genome of a hyper-thermophilic archaebacterium, pyrococcus horikoshii OT3", DNA RES., vol. 5, no. 2, 1998, pages 55 - 76, XP001002795 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004020621A1 (ja) * | 2002-08-30 | 2004-03-11 | Takara Bio Inc. | 耐熱性リボヌクレアーゼh |
CN100343388C (zh) * | 2002-08-30 | 2007-10-17 | 宝生物工程株式会社 | 热稳定的核糖核酸酶h |
WO2010026933A1 (ja) | 2008-09-03 | 2010-03-11 | タカラバイオ株式会社 | Rna検出用組成物 |
WO2014142261A1 (ja) | 2013-03-14 | 2014-09-18 | タカラバイオ株式会社 | 耐熱性のミスマッチエンドヌクレアーゼの利用方法 |
Also Published As
Publication number | Publication date |
---|---|
TWI310404B (en) | 2009-06-01 |
US8008055B2 (en) | 2011-08-30 |
JPWO2002022831A1 (ja) | 2004-01-22 |
EP2009107A3 (en) | 2009-03-18 |
AU2001286211A1 (en) | 2002-03-26 |
ATE411389T1 (de) | 2008-10-15 |
US7422888B2 (en) | 2008-09-09 |
KR20030031178A (ko) | 2003-04-18 |
EP1318197B1 (en) | 2008-10-15 |
KR100578476B1 (ko) | 2006-05-11 |
EP2009107A2 (en) | 2008-12-31 |
EP1318197A4 (en) | 2005-03-02 |
KR20060032663A (ko) | 2006-04-17 |
EP1318197A1 (en) | 2003-06-11 |
US20040038366A1 (en) | 2004-02-26 |
US20090098600A1 (en) | 2009-04-16 |
JP3910142B2 (ja) | 2007-04-25 |
KR100696390B1 (ko) | 2007-03-20 |
CN1474873A (zh) | 2004-02-11 |
CN1250726C (zh) | 2006-04-12 |
DE60136198D1 (en) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007004654A1 (ja) | 変異型pcna | |
US8008055B2 (en) | Thermotolerant ribonuclease H | |
JP7363063B2 (ja) | 変異型dnaポリメラーゼ | |
US7932071B2 (en) | Thermostable ribonuclease H from Archaeoglobus profundus | |
KR101303990B1 (ko) | 써모코커스 파시피쿠스 균주 유래의 dna 중합효소 유전자 변이체들 및 이의 이용 | |
JP5210530B2 (ja) | RrhJ1I制限・修飾酵素およびその遺伝子 | |
EP2084283A1 (en) | Mutant dna polymerases and their genes | |
JP3463951B2 (ja) | 耐熱性ピログルタミルペプチダーゼ及びその遺伝子 | |
JP2006288400A (ja) | 耐熱性リボヌクレアーゼh | |
KR100784168B1 (ko) | 열안정성이 증대된 신규 자일란 분해효소 | |
JP3762983B2 (ja) | Dnaヘリカーゼ | |
JP4452834B2 (ja) | 新規dna分解酵素 | |
JP2022550810A (ja) | 海洋性dnaポリメラーゼi | |
JPH0662847A (ja) | 古細菌由来の熱安定性リガーゼ | |
JP2022551588A (ja) | Dnaポリメラーゼおよびdnaポリメラーゼ由来3’-5’エキソヌクレアーゼ | |
KR101296882B1 (ko) | 써모코커스 와이오타푸엔시스 균주 유래의 dna 중합효소 변이체들 및 이의 이용 | |
KR100372777B1 (ko) | 아퀴펙스 파이로필러스로부터 분리된 내열성 디엔에이중합효소의 유전자 및 그로부터 유추되는 아미노산 서열 | |
JP5626263B2 (ja) | RrhJ1I修飾酵素およびその遺伝子 | |
EP3390628A1 (en) | Calcium independent pectinases with improved thermostability | |
JP2010088446A (ja) | 新規dna分解酵素 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020037003322 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001965599 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002527273 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10380430 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037003322 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018186904 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001965599 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020037003322 Country of ref document: KR |